Data viva — interpreting the phenylephrine evidence base

Stimulus

A table summarises the phenylephrine evidence spanning pharmacology, comparative trials and special populations. The pharmacology row: phenylephrine is a PURE ALPHA-1 agonist (taught Gq cascade to vasoconstriction), with no beta-1 activity so the blood-pressure rise triggers a baroreceptor-mediated reflex bradycardia (Lee-exact RR 4.79) and the cardiac output may fall (taught); the half-life is about 5 minutes (taught MAO metabolism) and dosing is per local formulary and protocol (taught; no pack dosing numbers). The obstetric row: phenylephrine is preferred over ephedrine for spinal-induced hypotension because it produces a higher umbilical artery pH (ephedrine crosses the placenta and causes fetal beta stimulation and metabolic acidosis). The older-adult row (Dong): vasopressor selection shapes postoperative delirium risk in the elderly. The shivering row (Kim): dexmedetomidine used for shivering produces a sympatholysis that may require a vasopressor, and a pure alpha-1 agent is reasonable where the heart rate should not rise. The preterm-neonatal row (King): cystic periventricular leukomalacia in the preterm infant and the pressure-passive cerebral circulation caution against rapid vasopressor swings. The anaphylaxis row (Baba): a Kounis syndrome case of allergic acute coronary syndrome with vasoplegia, where adrenaline rather than phenylephrine is the first-line drug. Interpret the data, rank the evidence by strength, and justify a clinical choice in three scenarios.^[9][6]